Skip to content

Braveheart Bio

US · BRVE #2845 by market cap Listed 2026
20.39 +1.12 +5.81%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 29 in the most recent period (2026/Q3).
  • Total institutional ownership rose 86.1 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
86.07% +86.07pp
Institutions
29 +29
As of
2026/Q3 vs. prior period

Holder types

VC/PE Fund60.44%
Mutual Fund16.46%
Individual/Insider14.87%
Public Company9.10%
Other12.85%

Top holders as of 2026-08-07

Forbion Capital Partners B.V. 26.74% · 21.83M sh
OrbiMed Advisors LLC 14.91% · 12.18M sh
Andreessen Horowitz LLC 12.53% · 10.23M sh
Travis Murdoch 10.21% · 8.33M sh
FMR 9.29% · 7.59M sh
Jiangsu Hengrui Pharmaceuticals Co.,Ltd 9.09% · 7.42M sh
Frazier Life Sciences Management, LP 6.26% · 5.11M sh
Capital Research 2.86% · 2.33M sh
David Malek 1.24% · 1.01M sh
Vanguard Capital Management, LLC 1.39% · 1.13M sh
James Rickey 0.86% · 703.58K sh
Jason Coloma 1.33% · 1.10M sh
Christopher Viehbacher 0.75% · 609.52K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

34 filings tracked · 22 buys · 0 sells

NameRoleStake
Forbion Capital Partners B.V. -- 26.74%
OrbiMed Advisors LLC -- 14.91%
Andreessen Horowitz LLC -- 12.53%
Travis Murdoch Chief Executive Officer 10.21%
Jason Coloma Former Director 1.33%
David Malek Director 1.24%
James Rickey Chief Financial Officer 0.86%
Christopher Viehbacher Independent Chairperson 0.75%
Michele Anderson Chief Development Officer 0.41%
David Lubner Independent Director 0.07%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-08-06 OrbiMed Advisors LLC -- Private Acquisition +1,940,000 $18.00
2026-08-06 OrbiMed Advisors LLC -- Derivative Exercise and Retained +9,132,420 --
2026-08-06 David Lubner Independent Director Private Acquisition +55,555 $18.00
2026-08-06 Christopher Viehbacher Independent Chairperson Private Acquisition +83,333 $18.00
2026-08-06 Jiangsu Hengrui Pharmaceuticals Co.,Ltd -- Derivative Exercise and Retained +7,420,091 --
2026-08-06 Forbion Capital Partners B.V. -- Private Acquisition +3,600,000 $18.00
2026-08-06 Forbion Capital Partners B.V. -- Derivative Exercise and Retained +17,123,287 --
2026-08-06 Andreessen Horowitz LLC -- Private Acquisition +1,100,000 $18.00
2026-08-06 Andreessen Horowitz LLC -- Derivative Exercise and Retained +9,132,420 --
2026-08-06 Andreessen Horowitz LLC -- Initial Statement of Beneficial 0 --
2026-08-06 David Malek Director Private Acquisition +4,166 $18.00
2026-08-06 James Rickey Chief Financial Officer Private Acquisition +27,777 $18.00
2026-08-06 Michele Anderson Chief Development Officer Private Acquisition +1,111 $18.00
2026-08-06 Travis Murdoch Chief Executive Officer Private Acquisition +83,333 $18.00
2026-08-04 OrbiMed Advisors LLC -- Initial Statement of Beneficial 0 --
2026-08-04 David Lubner Independent Director Other Derivative Acquisition +60,000 $18.00
2026-08-04 Christopher Viehbacher Independent Chairperson Other Derivative Acquisition +30,000 $18.00
2026-08-04 Christopher Viehbacher Independent Chairperson Initial Statement of Beneficial 0 --
2026-08-04 Erez Chimovits Independent Director Other Derivative Acquisition +30,000 $18.00
2026-08-04 Jiangsu Hengrui Pharmaceuticals Co.,Ltd -- Initial Statement of Beneficial 0 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Braveheart Bio discussion 0 comments

Add a comment